Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Jazz Pharmaceuticals’ Luvox CR Gets Feb. 29 Action Date

This article was originally published in The Pink Sheet Daily

Executive Summary

Company expects to launch the extended-release anti-anxiety medication in the first quarter, after FDA accepts response to “approvable” letter.

You may also be interested in...



Jazz/Solvay Gain Approval Of Luvox CR

Approval of anxiety/obsessive compulsive disorder drug comes a day ahead of its scheduled user fee date.

Jazz/Solvay Gain Approval Of Luvox CR

Approval of anxiety/obsessive compulsive disorder drug comes a day ahead of its scheduled user fee date.

Jazz Pharmaceuticals Gets Second “Approvable” Letter For Once-Daily Luvox

FDA seeks further information on chemistry, manufacturing and controls for Luvox CR NDA.

Related Content

Topics

UsernamePublicRestriction

Register

PS067217

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel